Contraceptive Technology Update – March 1, 2014
March 1, 2014
View Issues
-
Options might begin to emerge with new data out on LARC
The American College of Obstetricians and Gynecologists says that long-acting reversible contraception (LARC) methods are safe, effective, and appropriate options for teens, but some might perceive high discontinuation rates among younger women and therefore steer patients away from them. -
Interpregnancy interval — You can help women
New research indicates that provision of effective contraception at the time of postpartum follow-up is a key strategy for achieving optimal interpregnancy intervals. -
Check treatment options for dysmenorrhea
Early research indicates that women with moderate to severe menstrual cramps might find relief in vaginal administration of sildenafil citrate (Viagra, Pfizer), a drug commonly used for erectile dysfunction. -
Options being eyed for transdermal contraception
Transdermal contraception provides a family planning option that is not dependent on daily dosing. The only transdermal contraceptive approved in the United States is the Ortho Evra patch. -
Clinicians missing mark on sex talk with teens
In a study looking at discussions held between pediatricians and family medicine physicians and teen-age patients, results show less than two-thirds of such interactions included talk about sex, sexuality, or dating during annual visits. -
Contraceptive coverage heads to Supreme Court
With Congress in a seemingly perpetual state of deadlock, one of the most anticipated actions on federal reproductive health policy will instead be taken by the U.S. Supreme Court this spring. -
STI Quarterly: New data emerges on use of pre-exposure prophylaxis (PrEP)
No link seen between regimen use and increased sexual risk behavior -
STI Quarterly: What is the role of express STI testing?
Declining resources in the face of increasing demand are causing sexually transmitted infection (STI) clinics to review new strategies to maximize efficiency without compromising quality of care.